Ibandronsäure Stada (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic acid binds to hydroxyapatite at sites of active bone remodeling. When osteoclasts attach to the drug‑coated bone surface, the compound is taken up, disrupting the mevalonate pathway, leading to osteoclast apoptosis and a consequent decrease in bone resorption.

The dosing regimen for Ibandronsäure Stada is determined by the prescribing physician based on the patient’s clinical condition, renal function, and other individual factors. Only a qualified healthcare professional should set the dose and infusion schedule.

The safety of ibandronic acid in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women unless the potential benefit justifies the potential risk, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Ibandronsäure Stada is an intravenous bisphosphonate that offers a convenient dosing interval (typically once every three months) compared with more frequent oral bisphosphonates. Its efficacy in reducing vertebral and non‑vertebral fractures is comparable, while the safety profile is similar, with infusion‑related reactions being the most notable difference.

The product should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the solution. Before use, inspect the vial for particulate matter and ensure it is at the appropriate temperature for infusion.

Ibandronsäure Stada is given as an intravenous infusion over a short period, usually 15–30 minutes, under the supervision of a qualified healthcare professional. The infusion rate and total volume are defined by the prescribing physician and the product’s prescribing information.

Serious adverse events include acute phase reactions (high fever, hypotension), osteonecrosis of the jaw, and atypical femoral fractures. Renal impairment can also be aggravated, so renal function must be monitored before and during therapy.

Patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronic acid or any component of the formulation, and those with untreated hypocalcemia should not receive the product. Caution is also advised for individuals with active dental infections or recent jaw surgery.